Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …

Formation of distant metastases is by far the most common cause of cancer-related deaths.
The process of metastasis formation is complex, and within this complex process the …

The cytochrome P450 (CYP) enzymes are major players in drug metabolism. More than
2,000 mutations have been described, and certain single nucleotide polymorphisms (SNPs) …

The bone marrow microenvironment (BME) drives drug resistance in acute lymphoblastic
leukemia (ALL) through leukemic cell interactions with bone marrow (BM) niches, but the …

T-cell acute lymphoblastic leukemia (T-ALL) accounts for 15% and 25% of total childhood
and adult ALL cases, respectively. During T-ALL, patients are at risk of organ infiltration by …

The bone marrow (BM) microenvironment regulates the properties of healthy hematopoietic
stem cells (HSCs) localized in specific niches. Two distinct microenvironmental niches have …

Acute leukemias (both myeloid and lymphoblastic) are a group of diseases for which each
year more successful therapies are implemented. However, in a subset of cases the overall …

Extracellular matrix, via its receptors the integrins, has emerged as a crucial factor in cancer
development. The α2β1 integrin is a major collagen receptor that is widely expressed and …

Genetic lesions predisposing to pediatric B-cell acute lymphoblastic leukemia (B-ALL) arise
in utero, generating a clinically silent pre-leukemic phase. We here reviewed the role of the …

Abstract Phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR)
are two key components of the PI3K/Akt/mTOR signaling pathway. This signal transduction …